Janux Therapeutics Inc
JANX
Get informed when a big investor buys or sells
+ FollowMarket Cap$925.13M
Close$
$-3.69
123.1% downside
Current Fair Value
123.1% downsideOvervalued by 123.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $925.13 Million |
|---|---|
| Enterprise Value | $932.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 2.51 |
| Outstanding Shares | 62,665,717 |
Return
| Return on Equity | -16.84% |
|---|---|
| Return on Assets | -15.42% |
| Return on Invested Capital | -19.66% |
Valuation & Multiples
| P/E Ratio | -8.24 |
|---|---|
| PEG | -227.21 |
| Price to Sales | - |
| Price to Book Ratio | 1.06 |
| Enterprise Value to Revenue | 43.14 |
| Enterprise Value to EBIT | -4.89 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
$4.36 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$19.07 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 91.74% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.65%▼ 94.43% |
|---|---|
| Total Invested | $6.28M▼ 99.24% |
| Investors Holding | 27▼ 173.00% |
ESG Score
No data
About Janux Therapeutics Inc
16 employees